Apr 1, 2008|
Stockmarkets, inflation and more...
Indian stockmarkets continue to dance to the tunes of their global counterparts as was amply demonstrated in yesterday's trading session, which saw the BSE-Sensex shed nearly 725 points (down 4%) following the weakness in the US and European markets. In fact US markets were hampered on Friday following a profit warning from JC Penney, a large retailer in the US despite encouraging readings on personal incomes, which registered an increase. Having said that, consumer spending rose just 0.1%, the smallest rise since September 2006. Meanwhile, the Federal Reserve continues to be active in bailing out the financial system from its worst ever crisis and had announced that it would make an additional US$ 100 bn available to cash-deficient banks during the month of April, as part of its ongoing plan to help unfreeze the credit markets. This has, however, not insulated the US markets from bouts of volatility and this nervousness has had an effect on other markets across the globe as well.
India's inflation surged to 6.68% for the week ended March 15, 2008 marking a 13-month high. This is following 5.92% that was recorded a week earlier and has now dampened chances of the RBI softening interest rates. The spike has been attributed to rising food prices, which besides afflicting India has weighed heavy on world economies as well. A spurt in steel prices too has contributed to the rise in India's inflation. This is expected to put pressure on the central bank to suggest some monetary adjustments so that the impact of rising prices is lowered on consumers. Already the government has announced measures to reduce import duties on certain products. Whether this will cool down inflation remains to be seen. Meanwhile, given the firm crude oil prices, the pressure on domestic energy prices is also expected to increase, thus having the potential to increase inflation at a higher rate going forward.
R&D efforts of global pharma companies received a setback last week when it was reported that the cholesterol reducing drug 'Vytorin', a combination of Merck's 'Zocor' and Schering Plough's 'Zetia', was not found to be more effective than cheaper generic versions. These findings have been published after two years of study on the drug, which has elicited considerable criticism. 'Vytorin' is a blockbuster drug having generated revenues to the tune of US$ 5 bn. Global innovator companies are facing increasing pressure in recent times given the patent expiries of their blockbuster drugs resulting in nearly 90% erosion in prices and drying research pipelines. Many of them are resorting to a host of strategies, which include extending the patents on their blockbuster drugs, in-licensing molecules from small research companies, acquiring companies with a promising research pipeline and focusing on biotechnology, which is a very niche and highly lucrative field. The US FDA has also been stringent in approving new drugs in light of the 'Vioxx' debacle (Merck had to withdraw the drug from the market) and the controversy surrounding anti-diabetic drug 'Avandia', which has been associated with increasing the rate of heart attacks. Thus, the going may not be that easy for domestic pharma companies whose R&D programmes are still in their nascent stages.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 22, 2017
It's surprising Warren Buffett hasn't warned investors about the expensive stock market? Let us know why.
Aug 22, 2017
Post demonetisation, a cut in bank savings deposits rates was in the offing.
Aug 22, 2017
Today, we are attacked by one preposterous thing after another, each of them even more absurd than the last.
Aug 21, 2017
Most Indians who cannot find jobs, look at becoming self-employed.
More Views on News
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 10, 2017
Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407